contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


gubra-raises-financial-outlook-for-2024-1

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They primarily conduct research and development in the area of metabolic and fibrotic diseases. The company's product portfolio includes several brands and drugs, and the operations are conducted on a global level, with the largest presence in North America and the Nordic region. The headquarters are located in Hørsholm, Denmark.

Gubra

Today, Gubra announces an upgrade to its full-year 2024 financial outlook. Organic revenue growth for the CRO business is now expected to be 23-28% (previously 15-20%) and adjusted EBIT-margin...

<div class="mfn-preamble"><p><strong>Today, Gubra announces an upgrade to its full-year 2024 financial outlook. Organic revenue growth for the CRO business is now expected to be 23-28% (previously 15-20%) and adjusted EBIT-margin is expected to be 29-32% (previously 28-31%). For the Discovery &amp; Partnerships business, the 2024 outlook is unchanged.</strong></p></div><div class="mfn-body"><p>The upgrade to the CRO business follows high activity in the first half of 2024 and solid current trading and orderbook. The main growth driver is the Obesity area where Gubra is a leading provider of high-end preclinical Obesity services.</p><p><strong>Outlook for 2024</strong></p><table><tbody><tr><td rowspan="1" colspan="1"><strong>Key ratio</strong></td><td rowspan="1" colspan="1"><strong>New outlook for 2024</strong></td><td rowspan="1" colspan="1"><strong>Previous outlook for 2024*</strong></td></tr><tr><td rowspan="1" colspan="1"><strong>CRO Segment</strong></td><td rowspan="1" colspan="1"><strong>&nbsp;</strong></td><td rowspan="1" colspan="1"><strong>&nbsp;</strong></td></tr><tr><td rowspan="1" colspan="1">Organic revenue growth y/y</td><td rowspan="1" colspan="1">23-28%</td><td rowspan="1" colspan="1">15-20%</td></tr><tr><td rowspan="1" colspan="1">Adjusted EBIT-margin</td><td rowspan="1" colspan="1">29-32%</td><td rowspan="1" colspan="1">28-31%</td></tr><tr><td rowspan="1" colspan="1"><strong>Discovery &amp; Partnerships Segment</strong></td><td rowspan="1" colspan="1"><strong>&nbsp;</strong></td><td rowspan="1" colspan="1"><strong>&nbsp;</strong></td></tr><tr><td rowspan="1" colspan="1">Number of new partnerships per year</td><td rowspan="1" colspan="1">1-2</td><td rowspan="1" colspan="1">1-2</td></tr><tr><td rowspan="1" colspan="1">Total costs (adjusted)</td><td rowspan="1" colspan="1">DKK 160-170m</td><td rowspan="1" colspan="1">DKK 160-170m</td></tr><tr><td rowspan="1" colspan="1">Total costs excl. Amylin asset (adjusted)</td><td rowspan="1" colspan="1">DKK 115-125m</td><td rowspan="1" colspan="1">DKK 115-125m</td></tr></tbody></table><p>* Previous outlook announced 6 May 2024.</p><p>First half results 2024 will be published in Gubra’s half-year report 2024 on 22 August 2024.</p></div><div class="mfn-footer mfn-contacts mfn-cffe77846134"><p><strong class="mfn-heading-1">Contacts at Gubra</strong><br>Media: Sofia Pitt Boserup, <a rel="noopener" href="mailto:sbo@gubra.dk">sbo@gubra.dk</a>, +45 4188 9586<br>Investors: Kristian Borbos, <a rel="noopener" href="mailto:kbo@gubra.dk">kbo@gubra.dk</a>, +45 3080 8035</p></div><div class="mfn-footer mfn-about mfn-a42358512560"><p><strong class="mfn-heading-1">About Gubra</strong><br>Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery &amp; Partnerships (D&amp;P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&amp;P business. In 2023, Gubra had approx. 220 employees and revenue of DKK 205 million. See <a rel="noopener" href="http://www.gubra.dk">www.gubra.dk</a> for more information.</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that Gubra is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-21 17:12 CEST.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/4b435bfe-4408-4218-9741-769e7425c8e5/gubra-raises-financial-outlook-for-2024.pdf" class="mfn-generated mfn-primary">Gubra raises financial outlook for 2024</a></p></div>

Key ratio	New outlook for 2024	Previous outlook for 2024*
CRO Segment
Organic revenue growth y/y	23-28%	15-20%
Adjusted EBIT-margin	29-32%	28-31%
Discovery & Partnerships Segment
Number of new partnerships per year	1-2	1-2
Total costs (adjusted)	DKK 160-170m	DKK 160-170m
Total costs excl. Amylin asset (adjusted)	DKK 115-125m	DKK 115-125m